Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022139732 - DEVELOPMENT OF NANOMATERIAL FOR CONTROLLED RELEASE OF LUTEOLIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Publication Number WO/2022/139732
Publication Date 30.06.2022
International Application No. PCT/TR2021/051173
International Filing Date 10.11.2021
IPC
A61K 31/352 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
C08L 33/26 2006.1
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
33Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Compositions of derivatives of such polymers
24Homopolymers or copolymers of amides or imides
26Homopolymers or copolymers of acrylamide or methacrylamide
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C08L 33/26
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
33Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
24Homopolymers or copolymers of amides or imides
26Homopolymers or copolymers of acrylamide or methacrylamide
Applicants
  • EGE ÜNİVERSİTESİ [TR]/[TR]
Inventors
  • AKGÖL, Sinan
  • KUŞAT, Kevser
Agents
  • YALCINER, Ugur G. (YALCINER PATENT & CONSULTING LTD.)
Priority Data
2020/2170225.12.2020TR
2021/01587912.10.2021TR
Publication Language English (en)
Filing Language Turkish (TR)
Designated States
Title
(EN) DEVELOPMENT OF NANOMATERIAL FOR CONTROLLED RELEASE OF LUTEOLIN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
(FR) DÉVELOPPEMENT DE NANOMATÉRIAU POUR LA LIBÉRATION CONTRÔLÉE DE LUTÉOLINE DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
Abstract
(EN) The invention relates to the development of nanomaterials for the controlled release of luteolin used in the treatment of neurodegenerative diseases.
(FR) L'invention concerne le développement de nanomatériaux pour la libération contrôlée de lutéoline utilisée dans le traitement de maladies neurodégénératives.
Latest bibliographic data on file with the International Bureau